• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.

作者信息

Kudo Masatoshi

机构信息

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

出版信息

Liver Cancer. 2023 May 24;12(3):189-197. doi: 10.1159/000531225. eCollection 2023 Aug.

DOI:10.1159/000531225
PMID:37484877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10360452/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c3/10360452/45afcd236506/lic-2023-0012-0003-531225_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c3/10360452/afe71b09c9cb/lic-2023-0012-0003-531225_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c3/10360452/45afcd236506/lic-2023-0012-0003-531225_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c3/10360452/afe71b09c9cb/lic-2023-0012-0003-531225_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70c3/10360452/45afcd236506/lic-2023-0012-0003-531225_F01.jpg

相似文献

1
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.肝细胞癌切除或消融术后辅助使用阿替利珠单抗-贝伐珠单抗
Liver Cancer. 2023 May 24;12(3):189-197. doi: 10.1159/000531225. eCollection 2023 Aug.
2
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma.肝细胞癌根治性治疗后辅助使用阿替利珠单抗-贝伐珠单抗。
Hepatobiliary Surg Nutr. 2023 Jun 1;12(3):435-439. doi: 10.21037/hbsn-23-203. Epub 2023 May 22.
3
Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment.两例肝癌患者在接受阿替利珠单抗联合贝伐珠单抗治疗后，成功接受碳离子放疗。
Clin J Gastroenterol. 2023 Jun;16(3):407-415. doi: 10.1007/s12328-023-01768-z. Epub 2023 Feb 7.
4
Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.根治性肝切除术后阿替利珠单抗联合贝伐珠单抗辅助治疗的安全性和有效性。
Clin Res Hepatol Gastroenterol. 2023 Aug;47(7):102165. doi: 10.1016/j.clinre.2023.102165. Epub 2023 Jun 15.
5
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.索凡替尼联合贝伐珠单抗治疗后成功转化的肝细胞癌合并门静脉癌栓患者行转化手术：一例报告
World J Surg Oncol. 2022 Jul 12;20(1):228. doi: 10.1186/s12957-022-02691-2.
6
Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series.肝癌患者在使用乐伐替尼后接受阿替利珠单抗联合贝伐单抗治疗出现的甲状腺功能障碍：病例系列报道
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231164488. doi: 10.1177/2050313X231164488. eCollection 2023.
7
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
8
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
9
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
10
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗对比索拉非尼用于不可切除或转移性肝细胞癌患者的成本效果分析。
JAMA Netw Open. 2021 Apr 1;4(4):e214846. doi: 10.1001/jamanetworkopen.2021.4846.

引用本文的文献

1
Innovative rapid pathological assessment technology for hepatocellular carcinoma following comprehensive treatment guided by indocyanine green fluorescence imaging.吲哚菁绿荧光成像引导下综合治疗后肝细胞癌的创新快速病理评估技术
Updates Surg. 2025 Jul 7. doi: 10.1007/s13304-025-02301-2.
2
Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.肝细胞癌切除或消融术后复发高危患者辅助免疫治疗面临的挑战
Liver Cancer. 2024 Oct 24;13(6):573-578. doi: 10.1159/000542221. eCollection 2024 Dec.
3
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.

本文引用的文献

1
Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?不可切除肝细胞癌全身治疗方案的选择：病因学有影响吗？
Liver Cancer. 2022 Jun 13;11(4):283-289. doi: 10.1159/000525467. eCollection 2022 Jul.
2
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
3
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
日本肝细胞癌的当前治疗策略
Liver Cancer. 2023 Oct 3;12(6):497-509. doi: 10.1159/000534304. eCollection 2023 Dec.
4
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy.肝细胞癌患者的所有阶段都能从全身治疗联合局部区域治疗中获益。
Liver Cancer. 2023 Aug 12;12(5):395-404. doi: 10.1159/000533493. eCollection 2023 Oct.
5
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.肝细胞癌系统性治疗的新时代：从一线治疗到最佳序贯治疗。
Curr Oncol. 2023 Sep 26;30(10):8774-8792. doi: 10.3390/curroncol30100633.
阿替利珠单抗联合贝伐珠单抗治疗伴有 A 级和 B 级肝硬化的肝细胞癌患者的安全性和耐受性的初步证据：一项真实世界研究。
Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8.
4
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
5
Immunotherapies for hepatocellular carcinoma.肝细胞癌的免疫疗法
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.
6
Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma.肝细胞癌根治性治疗后的辅助免疫治疗。
Liver Cancer. 2021 Sep 6;10(5):399-403. doi: 10.1159/000518584. eCollection 2021 Sep.
7
Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.仑伐替尼治疗非病毒性感染且对免疫治疗反应不佳的肝细胞癌患者：一项回顾性对比研究。
Oncology. 2021;99(10):641-651. doi: 10.1159/000517494. Epub 2021 Aug 10.
8
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.免疫微环境可预测接受抗PD-1抗体治疗的肝细胞癌患者的生存情况。
Liver Cancer. 2021 Jul;10(4):380-393. doi: 10.1159/000516899. Epub 2021 Jun 9.
9
Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013).日本第22次全国原发性肝癌随访调查（2012 - 2013年）报告
Hepatol Res. 2022 Jan;52(1):5-66. doi: 10.1111/hepr.13675. Epub 2022 Jan 2.
10
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.